JP2008517613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517613A5 JP2008517613A5 JP2007538421A JP2007538421A JP2008517613A5 JP 2008517613 A5 JP2008517613 A5 JP 2008517613A5 JP 2007538421 A JP2007538421 A JP 2007538421A JP 2007538421 A JP2007538421 A JP 2007538421A JP 2008517613 A5 JP2008517613 A5 JP 2008517613A5
- Authority
- JP
- Japan
- Prior art keywords
- jak2
- variant
- sequence
- seq
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102200087780 rs77375493 Human genes 0.000 claims 39
- 238000000034 method Methods 0.000 claims 27
- 239000000523 sample Substances 0.000 claims 15
- 230000002071 myeloproliferative effect Effects 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 8
- 108010019437 Janus Kinase 2 Proteins 0.000 claims 7
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 7
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 6
- 208000037244 polycythemia vera Diseases 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 101150009057 JAK2 gene Proteins 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 206010028537 myelofibrosis Diseases 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008601 Polycythemia Diseases 0.000 claims 2
- 208000005485 Thrombocytosis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010024378 leukocytosis Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091061960 Naked DNA Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 229940000406 drug candidate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0411480 | 2004-10-27 | ||
| FR0411480A FR2877013A1 (fr) | 2004-10-27 | 2004-10-27 | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| PCT/EP2005/055586 WO2006045827A1 (fr) | 2004-10-27 | 2005-10-26 | Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009155912A Division JP5290884B2 (ja) | 2004-10-27 | 2009-06-30 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008517613A JP2008517613A (ja) | 2008-05-29 |
| JP2008517613A5 true JP2008517613A5 (enExample) | 2009-03-05 |
| JP5090171B2 JP5090171B2 (ja) | 2012-12-05 |
Family
ID=34953071
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538421A Expired - Lifetime JP5090171B2 (ja) | 2004-10-27 | 2005-10-26 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
| JP2009155912A Expired - Lifetime JP5290884B2 (ja) | 2004-10-27 | 2009-06-30 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
| JP2013003374A Expired - Lifetime JP6103691B2 (ja) | 2004-10-27 | 2013-01-11 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009155912A Expired - Lifetime JP5290884B2 (ja) | 2004-10-27 | 2009-06-30 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
| JP2013003374A Expired - Lifetime JP6103691B2 (ja) | 2004-10-27 | 2013-01-11 | 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US7781199B2 (enExample) |
| EP (2) | EP1692281B8 (enExample) |
| JP (3) | JP5090171B2 (enExample) |
| KR (1) | KR101203003B1 (enExample) |
| CN (1) | CN101072870B (enExample) |
| AT (1) | ATE382082T1 (enExample) |
| AU (1) | AU2005298636B2 (enExample) |
| BR (1) | BRPI0517398B8 (enExample) |
| CA (3) | CA2585062C (enExample) |
| DE (1) | DE602005004008T2 (enExample) |
| DK (1) | DK1692281T3 (enExample) |
| ES (1) | ES2296229T3 (enExample) |
| FR (1) | FR2877013A1 (enExample) |
| IL (1) | IL182761A0 (enExample) |
| MX (1) | MX2007005174A (enExample) |
| PL (1) | PL1692281T3 (enExample) |
| PT (1) | PT1692281E (enExample) |
| SI (1) | SI1692281T1 (enExample) |
| WO (1) | WO2006045827A1 (enExample) |
| ZA (1) | ZA200703433B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CN100497657C (zh) * | 2006-09-27 | 2009-06-10 | 北京大学人民医院 | 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针 |
| WO2008061196A2 (en) * | 2006-11-15 | 2008-05-22 | Eragen Biosciences, Inc. | Methods and kits for detecting jak2 nucleic acid |
| US8367078B2 (en) * | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
| KR101147277B1 (ko) * | 2007-07-13 | 2012-05-21 | 아크레이 가부시키가이샤 | Ｊａｋ２ 유전자의 변이 검출용 프로브 및 그 용도 |
| GB0820631D0 (en) * | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
| DK2272978T3 (da) | 2009-07-10 | 2012-07-23 | Biotrin Internat Ltd | Højfølsom hurtig isotermisk fremgangsmåde til påvisning af punktmutationer og SNP´er |
| WO2011067373A1 (fr) * | 2009-12-04 | 2011-06-09 | Assistance Publique - Hopitaux De Paris | Methode de detection d'une polyglobulie chez un chien |
| AU2011214254B2 (en) * | 2010-02-10 | 2016-06-09 | Genon Biotechnologies Oy | Dual activity kinase domains and uses thereof |
| US20120021413A1 (en) * | 2010-04-30 | 2012-01-26 | Arkray, Inc. | Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor |
| CA2805586C (en) * | 2010-07-16 | 2020-09-01 | Stichting Vu-Vumc | A method of analysing a blood sample of a subject for the presence of a disease marker |
| US10174365B2 (en) | 2011-03-18 | 2019-01-08 | Stichting Vu-Vumc | Method of analysing a blood sample of a subject for the presence of a disease marker |
| JP2013017395A (ja) * | 2011-07-07 | 2013-01-31 | Toyobo Co Ltd | 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法 |
| GB201116876D0 (en) * | 2011-09-30 | 2011-11-16 | Epistem Ltd | Mutational analysis of JAK2 |
| CN103243153B (zh) * | 2012-02-10 | 2014-11-05 | 复旦大学附属华山医院 | Jak2 v617f突变的检测应用 |
| WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
| EP2917341B1 (en) | 2012-11-08 | 2017-09-27 | Centre National de la Recherche Scientifique (CNRS) | New phosphodeoxyribosyltransferase mutant enzymes and uses thereof |
| US10106855B2 (en) | 2012-11-09 | 2018-10-23 | The Johns Hopkins University | Genetic assay to determine prognosis in Polycythemia Vera patients |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| RS59363B1 (sr) | 2012-12-07 | 2019-11-29 | Geron Corp | Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze |
| SG11201509556TA (en) | 2013-05-16 | 2015-12-30 | Mobelisk Llc | Modular tablet case |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| AU2016248317A1 (en) * | 2015-04-15 | 2017-11-09 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| CN107949643A (zh) | 2015-04-23 | 2018-04-20 | 奎斯特诊断投资股份有限公司 | 用于检测骨髓增殖性疾病中calr突变的方法和组合物 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| CN105441573A (zh) * | 2016-01-11 | 2016-03-30 | 武汉海吉力生物科技有限公司 | 用于检测人类jak2基因v617f突变的引物、探针及试剂盒 |
| CN109803674A (zh) * | 2016-06-10 | 2019-05-24 | Io生物技术公司 | Calr和jak2疫苗组合物 |
| TWI879717B (zh) | 2017-07-28 | 2025-04-11 | 美商傑龍公司 | 治療骨髓增生不良症候群之方法 |
| SG11202105573PA (en) | 2018-11-29 | 2021-06-29 | Geron Corp | Methods of treating myelodysplastic syndrome |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
| US5753441A (en) | 1994-08-12 | 1998-05-19 | Myriad Genetics, Inc. | 170-linked breast and ovarian cancer susceptibility gene |
| AU6407696A (en) | 1995-07-07 | 1997-02-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method of identifying inhibitors of the jak-stat signal transduction pathway |
| US5914393A (en) * | 1995-12-05 | 1999-06-22 | Incyte Pharmaceuticals, Inc. | Human Jak2 kinase |
| FI104718B (fi) * | 1998-06-18 | 2000-03-31 | Orion Yhtymae Oyj | [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä |
| US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| CA2306446A1 (en) | 1998-09-25 | 2000-04-06 | Massachusetts Institute Of Technology | Methods and products related to genotyping and dna analysis |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| CN1440287A (zh) * | 2000-06-30 | 2003-09-03 | 辉瑞大药厂 | 治疗外周血管疾病、外周神经病和自主神经病的方法 |
| US20030012788A1 (en) | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| US20020090622A1 (en) | 2000-08-23 | 2002-07-11 | Monisola Adeokun | Chemical compounds |
| US20050235375A1 (en) * | 2001-06-22 | 2005-10-20 | Wenqiong Chen | Transcription factors of cereals |
| WO2004063324A2 (en) | 2002-05-03 | 2004-07-29 | Gene Logic, Inc. | Canine gene microarrays |
| AU2003256453A1 (en) | 2002-07-03 | 2004-01-23 | The Trustees Of Columbia University In The City Of New York | Methods for identifying modulators of mda-7 mediated apoptosis |
| EP1572957A4 (en) | 2002-08-27 | 2007-10-10 | Bristol Myers Squibb Pharma Co | IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS INTERACTING WITH AND / OR MODULATING TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS IN MAMMARY CELLS |
| US7537891B2 (en) | 2002-08-27 | 2009-05-26 | Bristol-Myers Squibb Company | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
| US20060019284A1 (en) | 2004-06-30 | 2006-01-26 | Fei Huang | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells |
| FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| US20070248961A1 (en) | 2006-04-20 | 2007-10-25 | Maher Albitar | Methods for detecting mutations in JAK2 nucleic acid |
| WO2011091332A2 (en) * | 2010-01-22 | 2011-07-28 | Chromatin, Inc. | Novel centromeres and methods of using the same |
-
2004
- 2004-10-27 FR FR0411480A patent/FR2877013A1/fr active Pending
-
2005
- 2005-10-26 DE DE602005004008T patent/DE602005004008T2/de not_active Expired - Lifetime
- 2005-10-26 AT AT05815749T patent/ATE382082T1/de active
- 2005-10-26 JP JP2007538421A patent/JP5090171B2/ja not_active Expired - Lifetime
- 2005-10-26 CA CA2585062A patent/CA2585062C/fr not_active Expired - Lifetime
- 2005-10-26 CA CA2647086A patent/CA2647086C/fr not_active Expired - Lifetime
- 2005-10-26 CA CA2754028A patent/CA2754028A1/fr not_active Abandoned
- 2005-10-26 WO PCT/EP2005/055586 patent/WO2006045827A1/fr not_active Ceased
- 2005-10-26 EP EP05815749A patent/EP1692281B8/fr not_active Expired - Lifetime
- 2005-10-26 BR BRPI0517398A patent/BRPI0517398B8/pt active IP Right Grant
- 2005-10-26 PL PL05815749T patent/PL1692281T3/pl unknown
- 2005-10-26 AU AU2005298636A patent/AU2005298636B2/en not_active Expired
- 2005-10-26 PT PT05815749T patent/PT1692281E/pt unknown
- 2005-10-26 SI SI200530129T patent/SI1692281T1/sl unknown
- 2005-10-26 MX MX2007005174A patent/MX2007005174A/es active IP Right Grant
- 2005-10-26 ES ES05815749T patent/ES2296229T3/es not_active Expired - Lifetime
- 2005-10-26 EP EP07118874A patent/EP1895000A1/fr not_active Withdrawn
- 2005-10-26 DK DK05815749T patent/DK1692281T3/da active
- 2005-10-26 US US10/580,458 patent/US7781199B2/en active Active
- 2005-10-26 KR KR1020077011851A patent/KR101203003B1/ko not_active Expired - Lifetime
- 2005-10-26 CN CN2005800420223A patent/CN101072870B/zh not_active Expired - Lifetime
-
2007
- 2007-04-23 IL IL182761A patent/IL182761A0/en unknown
- 2007-04-26 ZA ZA200703433A patent/ZA200703433B/xx unknown
- 2007-11-02 US US11/934,359 patent/US7429456B2/en not_active Expired - Lifetime
-
2008
- 2008-09-19 US US12/234,616 patent/US8637235B2/en active Active
-
2009
- 2009-06-30 JP JP2009155912A patent/JP5290884B2/ja not_active Expired - Lifetime
-
2011
- 2011-08-19 US US13/213,841 patent/US8466338B2/en not_active Expired - Lifetime
-
2013
- 2013-01-11 JP JP2013003374A patent/JP6103691B2/ja not_active Expired - Lifetime
- 2013-02-15 US US13/768,709 patent/US8852931B2/en not_active Expired - Lifetime
-
2014
- 2014-01-27 US US14/164,880 patent/US10364430B2/en not_active Expired - Lifetime
-
2019
- 2019-05-29 US US16/424,976 patent/US10563200B2/en not_active Expired - Lifetime
-
2020
- 2020-01-06 US US16/734,854 patent/US11162100B2/en not_active Expired - Lifetime
-
2021
- 2021-09-29 US US17/488,839 patent/US20220042016A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517613A5 (enExample) | ||
| AU2011312504B2 (en) | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease | |
| JP6219824B2 (ja) | びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）患者における抗−ｃｄ２０療法に対する応答の予測 | |
| JP6216486B2 (ja) | 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法 | |
| CA2585062A1 (fr) | Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez | |
| US20170114417A1 (en) | Pkn1 fusions | |
| JPWO2012157684A1 (ja) | 血中ｄｎａの定量的検出による悪性新生物の病勢の進行を評価する方法 | |
| KR102885025B1 (ko) | 유전적 조절 | |
| US20150218651A1 (en) | Use of dna in circulating exosomes as a diagnostic marker for metastatic disease | |
| JP2014082984A (ja) | 新規ｎｔｒｋ２活性化変異の検出法 | |
| AU2015332624A1 (en) | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide | |
| US20240131050A1 (en) | Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease | |
| US20170058361A1 (en) | Polypeptides and Antibodies for Assessing Predisposition for Myelodysplastic Syndromes or Myelogenous Tumor, and Method for Screening Therapeutic Drugs Therefor | |
| CA2980393A1 (en) | Methods for diagnosing and treating follicular lymphoma | |
| JP2013226108A (ja) | 新規ｎｔｒｋ２活性化変異の検出法 | |
| WO2016042114A1 (en) | Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis | |
| JP6449147B2 (ja) | Ｔ細胞リンパ腫の検出方法 | |
| CN113981071B (zh) | Csf1r相关基因突变作为诊断cvm的标志物及其应用 | |
| DK3277835T3 (en) | GENETIC PREDICTORS OF A REACTION ON TREATMENT WITH CRHR1 ANTAGONISTS | |
| TWI479024B (zh) | 檢測ｐ／ｐ血型的方法及其檢測套組 | |
| JP2008504838A (ja) | Ｐｒｋｃｂ１をコードするヒト自閉症感受性遺伝子およびその使用 | |
| KR20190086569A (ko) | 암 진단에서 후생적 염색체 상호 작용의 적용 | |
| JP6017117B2 (ja) | 炎症性腸疾患患者におけるアザチオプリン（ａｚｔ）の血中濃度の安定性を予測するジェネティックバイオマーカー | |
| CN108251519B (zh) | 轴前多指病的致病基因及其用途 | |
| KR20150113561A (ko) | 방광암 재발 진단 마커 |